Shake­up at Chi­na FDA af­ter chief vaults to the helm of a reg­u­la­to­ry um­brel­la group, new agency head named

Four days ago, Chi­na’s Con­gress passed a mas­sive gov­ern­ment over­haul that con­sol­i­dates the du­ties of Chi­na’s FDA un­der the um­brel­la of a mar­ket su­per­vi­sion ad­min­is­tra­tion and spits out a sep­a­rate drug reg­u­la­tor. To­day, news came out that for­mer CF­DA chief Bi Jingquan will head that um­brel­la agency while one of his deputies, Jiao Hong, will take up the new­ly cre­at­ed Chi­na Drug Ad­min­is­tra­tion.

First ap­point­ed to the CF­DA in 2015, Bi has been the face of re­form at the drug reg­u­la­tor, vow­ing to speed up do­mes­tic in­no­va­tion and en­cour­age for­eign in­vest­ment while re­main­ing strict on drug safe­ty. Clear­ing up the back­log of clin­i­cal tri­al and mar­ket­ing ap­pli­ca­tions, ac­cept­ing da­ta from over­seas tri­al sites and sanc­tion­ing con­tract man­u­fac­tur­ing agree­ments are among the most well-known pol­i­cy changes dur­ing his tenure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER